This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Oliviero E. Varnier, MD; Giovanni Melioli, MD; Annalisa Merli, PhD; Gian Carlo Schito, MD
Institute of Microbiology School of Medicine

Gabriela Tudor, PhD
National Institute for Cancer Research

Elio Boeri, MD; Angelo C. Molinari, MD; Pier Giorio Mori, MD
Hemophilia Center Gaslini Institute Genova, Italy

JAMA. 1985;254(11):1449-1450.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Seroconversion for antibody to human T-cell lymphotropic virus type III (HTLV-III) in hemophiliacs began shortly after the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic among homesexual men and intravenous drug users (1979-1980). The first case of seropositivity was observed in 1978 in a 2-year-old child who had received blood transfusions as well as factor VIII concentrate.¹ The seropositivity among European hemophiliacs has been reported to date back to 1981^2,3 following exposure to HTLV-III via some factor VIII concentrates obtained from the United States.⁴

We have tested several sequentially collected serum samples (1979 to 1985) from about 100 Italian hemo

Detection of Anti-HTLV-III Antibodies by ELISA and Western Blot Assays^* Intensity Score for Antibodies to HTLV-III Date of ELISA Serum Collection Index p15 p24 p31 p41 p55 p61 10/28/80 4.7 2 1 0 0 0 0 3/1/85 >15 4 1 3 4 2 2 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?